← All trials
NCT04501120
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2020
- Primary completion
- Aug 31, 2022
- Completion date
- Aug 31, 2023
- First posted
- Aug 6, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 105
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Government of ChinaStudy director
- Government of ChinaCollaborator
- Suzhou Yasheng Pharmaceutical Co., LtdStudy director
- Suzhou Yasheng Pharmaceutical Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.